Abstract: The present disclosure relates to an electrode for a secondary battery with improved rapid charging performance, a method of manufacturing the same, and a secondary battery including the same, and provides an electrode for a secondary battery including a current collector, an electrode active material layer located on at least one surface of the current collector, and a binder layer located on at least one surface of the current collector and protruding from at least one end of the electrode active material layer, in which the binder layer satisfies the following Expression 1. [Expression 1] CA/B? 0.6 (In Expression 1, CA is wt % of a conductive material in the binder layer, and B is wt % of a binder in the binder layer, based on a total weight of the binder layer).

Abstract: An aerosol generating device includes a housing including an accommodation space in which an aerosol generating article is accommodated and an air flow path through which fluid moves inside the housing, wherein a volume of the air flow path is variable.

Abstract: Provided is a method of controlling a temperature of a heater included in an aerosol generation device according to a type of cigarette. The method includes receiving temperature profiles of different types of cigarette from a user terminal; sensing a cigarette coupled to the heater after receiving the temperature profiles; identifying a type of the sensed cigarette; selecting a temperature profile corresponding to the identified type from among the temperature profiles; and controlling power supplied from a battery to the heater according to the selected temperature profile.

Abstract: An aerosol generating device includes: a housing including a hole for receiving an aerosol generating article and a guide apart from the hole; and a cover configured to move along the guide between a first position and a second position to open or close the hole, wherein the hole is open when the cover is located in the first position, and the hole is closed when the cover is located in the second position.

Abstract: An aerosol generating device includes: a housing including a hole for receiving an aerosol generating article and a guide apart from the hole; and a cover configured to move along the guide between a first position and a second position to open or close the hole, wherein the hole is open when the cover is located in the first position, and the hole is closed when the cover is located in the second position.

Abstract: The present invention relates to a secondary battery comprising a cathode, an anode and a separator interposed between the cathode and the anode, wherein the anode comprises an anode current collector and an anode mixture layer formed on at least one surface of the anode current collector, the anode mixture layer comprises an anode active material, a binder, and a conductive material, a loading amount of the anode mixture layer is 5 mg/cm2 to 15 mg/cm2, and value R of the anode mixture layer is 3,000 or less, wherein R means (permeability of the anode mixture layer)×(current density of a battery)2. According to the present invention, an overvoltage phenomenon of an anode surface and the deposition of lithium metal caused thereby can be prevented so that charging can be performed with a higher current, and thus rapid charging performance is improved, and lifespan is excellent even in the same current.

Abstract: The present disclosure provides compounds of Formula (I); or a pharmaceutically acceptable salt thereof, wherein each of Ring A, Ring B, Ra, Rb, L, R1, R2, m, and n is defined herein, pharmaceutical compositions thereof, methods of inhibiting ROCK1 and/or ROCK2, and methods of treating a ROCK1- and/or ROCK2-mediated disease or disorder.

Abstract: The present invention provides compounds having formula (I): and pharmaceutically acceptable salts thereof, wherein Cy1, Cy2, Cy3, R, R1, R2, R3, A1 and A2 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases in which inhibiting ROCK1, ROCK2, or ROCK1/2 has a therapeutically useful role.

Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving abnormal or excessive fibrosis.

Abstract: The present invention provides compounds having formula (I): and pharmaceutically acceptable salts thereof, wherein Cy1, Cy2, Cy3, R, R1, R2, and R3 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases in which inhibiting ROCK1, ROCK2, or ROCK1/2 has a therapeutically useful role.

Abstract: The present disclosure provides solid forms of (E)-3-[2-(2-thienyl)vinyl]-1H-pyrazole, compositions thereof, and methods of making and using the same.

Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis and proliferation, and where anti-fibrotic or anti-proliferative activity is beneficial.

Abstract: The present disclosure provides solid forms of (E)-3-[2-(2-thienyl)vinyl]-1H-pyrazole, compositions thereof, and methods of making and using the same.

Abstract: The present disclosure provides solid forms of (E)-3-[2-(2-thienyl)vinyl]-1H-pyrazole, compositions thereof, and methods of making and using the same.

Abstract: The present disclosure provides solid forms of (E)-3-[2-(2-thienyl)vinyl]-1H-pyrazole, compositions thereof, and methods of making and using the same.

Abstract: The present invention provides compounds having formula (I): and pharmaceutically acceptable salts thereof, wherein Cy1, Cy2, Cy3, R, R1, R2, R3, A1 and A2 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases in which inhibiting ROCK1, ROCK2, or ROCK1/2 has a therapeutically useful role.

Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving abnormal or excessive fibrosis.

Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis and proliferation, and where anti-fibrotic or anti-proliferative activity is beneficial.

Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving abnormal or excessive fibrosis.

Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving abnormal or excessive fibrosis.